A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater than or Equal to 50%
Fase: Phase II-III clinical trials
Struttura Principale: Oncologia Medica Toraco-Polmonare
Farmaco: MK-2870 (sacituzumab tirumotecan)
Pembrolizumab
Patologie: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
PI: Dr. Giuseppe Lo Russo
This trial is testing MK-2870 (sacituzumab tirumotecan, also called sac-TMT) administered in combination with pembrolizumab (pembro) or pembro as monotherapy in people with non-small cell lung cancer (NSCLC) spread to other parts of the body.
Which drug you receive will depend on which group you are in. This trial have 2 groups:
- Group 1 will receive MK-2870 in combination with pembro
- Group 2 will receive pembro as monotherapy
Last update: 20/05/2025